IL2 and graft versus host disease: IL2 (Aldesleukin) was administered during the cycles 4 to 6 on the days +6, +8 and +10 of the corresponding cycle at 1 × 106 IU/m2/d subcutaneously (s.c.), only in patients with no signs of severe acute GvHD (Grades 3–4) or extensive chronic GvHD.